港股新上市公司派格生物医药-B（02565）今日迎来挂牌首日，却遭遇"开门黑"。该股在交易时段内大跌15%，引发市场关注。
派格生物医药-B此前公布的招股结果显示，公司IPO定价为每股15.6港元，公开发售部分获得743.78倍超额认购，一手中签率仅为8%。然而，尽管认购热情高涨，但股价在上市首日即告破发。开盘价为13港元，较发行价下跌16.67%，随后继续下探。
分析人士指出，派格生物医药-B上市首日股价大跌，可能与以下因素有关：一是港股市场近期表现疲软，投资者情绪谨慎；二是生物医药板块估值普遍较高，市场对新股定价存在分歧；三是高额超额认购可能推高了投资者预期，导致上市后获利回吐压力加大。值得注意的是，该公司核心产品PB-119（用于治疗2型糖尿病的长效GLP-1受体激动剂）已进入商业化后期，其市场前景将是影响未来股价走势的关键因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.